After meeting with the agency, the firm is optimistic it can submit a BLA for isaralgagene civaparvovec in the second half of 2025 using an intermediate endpoint.
Through a new partnership, Caris will use its comprehensive genomic profiling tests to sequence more than 10,000 early-stage breast tumors collected in TAILORx.
The strategic shift will allow the firm to focus on advancing a newly announced in vivo gene-editing therapy candidate that's in preclinical development.
NEW YORK – Cancer Research UK and Australian charity the Minderoo Foundation said on Wednesday they are collectively committing approximately £3.4 million (about $4.4 million) to fund an adaptive ...
The companies will study genetic associations linked to autoimmune diseases to identify target genes as well as patients most likely to respond to therapy.